Corrigendum to “Naphthoquinone-tyrptophan reduces neurotoxic Aβ*56 levels and improves cognition in Alzheimer's disease animal model” Neurobiol Dis. 46(3) (2012):663-72

The authors regret that we have become aware that while paper [1] was cited in this publication as a previous work, it was not explicitly specified that the control of Aβ only (without inhibitor) presented in Fig. 1C and D was the same one used in paper [1] in Fig. 1A and 1C as a control (without inhibotor). They reflect one set of experiments performed by the first author of the two publications that included two different inhibitors (naphthoquinone-tyrptophan in paper [1] and chloro-naphthoquinone-tyrptophan in the current publication [2]) and one control. The authors would like to apologise for any inconvenience caused. [1] Scherzer-Attali, R., Pellarin, R., Convertino, M., Frydman-Marom, A., Egoz-Matia, N., Peled, S., Levy-Sakin, M., Shalev, D.E., Caflisch, A., Gazit, E. and Segal, D., 2010. Complete phenotypic recovery of an Alzheimer's disease model by a quinone-tryptophan hybrid aggregation inhibitor. PloS One, 5(6), 11101.